Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Moser T, Seiberl M, Feige J, Bieler L, Radlberger RF, O'Sullivan C, Pilz G, Harrer A, Schwenker K, Haschke-Becher E, Machegger L, Grimm J, Redlberger-Fritz M, Buchmann A, Khalil M, Kvas E, Trinka E, Wipfler P. Moser T, et al. Front Immunol. 2021 Aug 26;12:718895. doi: 10.3389/fimmu.2021.718895. eCollection 2021. Front Immunol. 2021. PMID: 34512642 Free PMC article. Clinical Trial.
Virological surveillance of influenza viruses in the WHO European Region in 2019/20 - impact of the COVID-19 pandemic.
Melidou A, Pereyaslov D, Hungnes O, Prosenc K, Alm E, Adlhoch C, Fielding J, Sneiderman M, Martinuka O, Celentano LP, Pebody R; WHO European Region influenza surveillance network; WHO European Region Influenza Surveillance Network author list. Melidou A, et al. Euro Surveill. 2020 Nov;25(46):2001822. doi: 10.2807/1560-7917.ES.2020.25.46.2001822. Euro Surveill. 2020. PMID: 33213683 Free PMC article.
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T. Wacheck V, et al. J Infect Dis. 2010 Feb 1;201(3):354-62. doi: 10.1086/649428. J Infect Dis. 2010. PMID: 20039806 Clinical Trial.
Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H. Lagler H, et al. Vaccine. 2012 Nov 6;30(48):6864-70. doi: 10.1016/j.vaccine.2012.09.005. Epub 2012 Sep 16. Vaccine. 2012. PMID: 22989690
Tick-borne encephalitis (TBE) and hepatitis B nonresponders feature different immunologic mechanisms in response to TBE and influenza vaccination with involvement of regulatory T and B cells and IL-10.
Garner-Spitzer E, Wagner A, Paulke-Korinek M, Kollaritsch H, Heinz FX, Redlberger-Fritz M, Stiasny K, Fischer GF, Kundi M, Wiedermann U. Garner-Spitzer E, et al. J Immunol. 2013 Sep 1;191(5):2426-36. doi: 10.4049/jimmunol.1300293. Epub 2013 Jul 19. J Immunol. 2013. PMID: 23872054
Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers.
Radner H, Sieghart D, Jorda A, Fedrizzi C, Hasenöhrl T, Zdravkovic A, Redlberger-Fritz M, Puchammer-Stoeckl E, Anderle K, Bergmann F, Firbas C, Jordakieva G, Wagner B, Haslacher H, Perkmann T, Heinz LX, Bonelli M, Crevenna R, Aletaha D, Zeitlinger M. Radner H, et al. Among authors: redlberger fritz m. Clin Microbiol Infect. 2023 May;29(5):635-641. doi: 10.1016/j.cmi.2022.12.008. Epub 2022 Dec 9. Clin Microbiol Infect. 2023. PMID: 36509374 Free article. Clinical Trial.
Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H. Lagler H, et al. Vaccine. 2011 Sep 16;29(40):6888-93. doi: 10.1016/j.vaccine.2011.07.050. Epub 2011 Jul 29. Vaccine. 2011. PMID: 21803100
51 results